The miRNA network: micro-regulator of cell signaling in cancer

References

• Higgs DR, Engel JD, Stamatoyannopoulos G. Thalassaemia. Lancet 2012;379(9813):373-83
   PubMed Web of Science ®Google Scholar
• Zilfou JT, Lowe SW. Tumor suppressive functions of p53. Cold Spring Harb Perspect Biol 2009;1(5):a001883
   PubMed Web of Science ®Google Scholar
• Beckerman R, Prives C. Transcriptional regulation by p53. Cold Spring Harb Perspect Biol 2010;2(8):a000935
   PubMed Web of Science ®Google Scholar
• Vousden KH, Prives C. Blinded by the light: the growing complexity of p53. Cell 2009;137(3):413-31
   PubMed Web of Science ®Google Scholar
• Toledo F, Wahl GM. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat Rev Cancer 2006;6(12):909-23
   PubMed Web of Science ®Google Scholar
• Levine AJ, Hu W, Feng Z. The P53 pathway: what questions remain to be explored? Cell Death Differ 2006;13(6):1027-36
   PubMed Web of Science ®Google Scholar
• Petitjean A, Achatz MI, Borresen-Dale AL, et al. TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene 2007;26(15):2157-65
   PubMed Web of Science ®Google Scholar
• Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;116(2):281-97
   PubMed Web of Science ®Google Scholar
• Fabbri M, Croce CM, Calin GA. MicroRNAs. Cancer J 2008;14(1):1-6
   PubMed Web of Science ®Google Scholar
• Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009;136(2):215-33
   PubMed Web of Science ®Google Scholar
• Wightman B, Ha I, Ruvkun G. Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell 1993;75(5):855-62
   PubMed Web of Science ®Google Scholar
• Guo H, Ingolia NT, Weissman JS, Bartel DP. Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature 2010;466(7308):835-40
   PubMed Web of Science ®Google Scholar
• Calin GA, Sevignani C, Dumitru CD, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA 2004;101(9):2999-3004
   PubMed Web of Science ®Google Scholar
• Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature 2005;435(7043):834-8
   PubMed Web of Science ®Google Scholar
• Schee K, Fodstad O, Flatmark K. MicroRNAs as biomarkers in colorectal cancer. Am J Pathol 2010;177(4):1592-9
   PubMedGoogle Scholar
• Hou J, Lin L, Zhou W, et al. Identification of miRNomes in human liver and hepatocellular carcinoma reveals miR-199a/b-3p as therapeutic target for hepatocellular carcinoma. Cancer Cell 2011;19(2):232-43
   PubMed Web of Science ®Google Scholar
• O’Connell RM, Rao DS, Chaudhuri AA, Baltimore D. Physiological and pathological roles for microRNAs in the immune system. Nat Rev Immunol 2010;10(2):111-22
   PubMed Web of Science ®Google Scholar
• Yoo AS, Sun AX, Li L, et al. MicroRNA-mediated conversion of human fibroblasts to neurons. Nature 2011;476(7359):228-31
   PubMed Web of Science ®Google Scholar
• Johnnidis JB, Harris MH, Wheeler RT, et al. Regulation of progenitor cell proliferation and granulocyte function by microRNA-223. Nature 2008;451(7182):1125-9
   PubMed Web of Science ®Google Scholar
• Wang JX, Jiao JQ, Li Q, et al. miR-499 regulates mitochondrial dynamics by targeting calcineurin and dynamin-related protein-1. Nat Med 2011;17(1):71-8
   PubMed Web of Science ®Google Scholar
• Gee HE, Camps C, Buffa FM, et al. MicroRNA-10b and breast cancer metastasis. Nature 2008;455(7216):E8-9. author reply E9
   PubMedGoogle Scholar
• Ma L, Teruya-Feldstein J, Weinberg RA. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 2007;449(7163):682-8
   PubMed Web of Science ®Google Scholar
• Hammond SM. MicroRNAs as tumor suppressors. Nat Genet 2007;39(5):582-3
   PubMed Web of Science ®Google Scholar
• Zhang B, Pan X, Cobb GP, Anderson TA. microRNAs as oncogenes and tumor suppressors. Dev Biol 2007;302(1):1-12
   PubMed Web of Science ®Google Scholar
• Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006;6(11):857-66
   PubMed Web of Science ®Google Scholar
• Lee YS, Dutta A. MicroRNAs in cancer. Annu Rev Pathol 2009;4:199-227
   PubMed Web of Science ®Google Scholar
• Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005;120(1):15-20
   PubMed Web of Science ®Google Scholar
• Fabbri M, Garzon R, Cimmino A, et al. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci USA 2007;104(40):15805-10
   PubMed Web of Science ®Google Scholar
• Gebeshuber CA, Zatloukal K, Martinez J. miR-29a suppresses tristetraprolin, which is a regulator of epithelial polarity and metastasis. EMBO Rep 2009;10(4):400-5
   PubMed Web of Science ®Google Scholar
• Hobert O. miRNAs play a tune. Cell 2007;131(1):22-4
   PubMedGoogle Scholar
• Bushati N, Cohen SM. microRNA functions. Annu Rev Cell Dev Biol 2007;23:175-205
   PubMed Web of Science ®Google Scholar
• Borchert GM, Lanier W, Davidson BL. RNA polymerase III transcribes human microRNAs. Nat Struct Mol Biol 2006;13(12):1097-101
   PubMed Web of Science ®Google Scholar
• Gregory RI, Yan KP, Amuthan G, et al. The Microprocessor complex mediates the genesis of microRNAs. Nature 2004;432(7014):235-40
   PubMed Web of Science ®Google Scholar
• Han J, Lee Y, Yeom KH, et al. Molecular basis for the recognition of primary microRNAs by the Drosha-DGCR8 complex. Cell 2006;125(5):887-901
   PubMed Web of Science ®Google Scholar
• Lund E, Guttinger S, Calado A, et al. Nuclear export of microRNA precursors. Science 2004;303(5654):95-8
   PubMed Web of Science ®Google Scholar
• Kim VN. MicroRNA biogenesis: coordinated cropping and dicing. Nat Rev Mol Cell Biol 2005;6(5):376-85
   PubMed Web of Science ®Google Scholar
• Martinez J, Tuschl T. RISC is a 5’ phosphomonoester-producing RNA endonuclease. Genes Dev 2004;18(9):975-80
   PubMed Web of Science ®Google Scholar
• Lytle JR, Yario TA, Steitz JA. Target mRNAs are repressed as efficiently by microRNA-binding sites in the 5’ UTR as in the 3’ UTR. Proc Natl Acad Sci USA 2007;104(23):9667-72
   PubMed Web of Science ®Google Scholar
• Tay Y, Zhang J, Thomson AM, et al. MicroRNAs to Nanog, Oct4 and Sox2 coding regions modulate embryonic stem cell differentiation. Nature 2008;455(7216):1124-8
   PubMed Web of Science ®Google Scholar
• Suzuki HI, Yamagata K, Sugimoto K, et al. Modulation of microRNA processing by p53. Nature 2009;460(7254):529-33
   PubMed Web of Science ®Google Scholar
• Fukuda T, Yamagata K, Fujiyama S, et al. DEAD-box RNA helicase subunits of the Drosha complex are required for processing of rRNA and a subset of microRNAs. Nat Cell Biol 2007;9(5):604-11
   PubMedGoogle Scholar
• Chen X, Guo X, Zhang H, et al. Role of miR-143 targeting KRAS in colorectal tumorigenesis. Oncogene 2009;28(10):1385-92
   PubMed Web of Science ®Google Scholar
• Junttila MR, Evan GI. p53–a Jack of all trades but master of none. Nat Rev Cancer 2009;9(11):821-9
   PubMed Web of Science ®Google Scholar
• He L, He X, Lim LP, et al. A microRNA component of the p53 tumour suppressor network. Nature 2007;447(7148):1130-4
   PubMed Web of Science ®Google Scholar
• Yamakuchi M, Lotterman CD, Bao C, et al. P53-induced microRNA-107 inhibits HIF-1 and tumor angiogenesis. Proc Natl Acad Sci USA 2010;107(14):6334-9
   PubMed Web of Science ®Google Scholar
• Kim T, Veronese A, Pichiorri F, et al. p53 regulates epithelial-mesenchymal transition through microRNAs targeting ZEB1 and ZEB2. J Exp Med 2011;208(5):875-83
   PubMed Web of Science ®Google Scholar
• Bommer GT, Gerin I, Feng Y, et al. p53-mediated activation of miRNA34 candidate tumor-suppressor genes. Curr Biol 2007;17(15):1298-307
   PubMed Web of Science ®Google Scholar
• Chang TC, Wentzel EA, Kent OA, et al. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell 2007;26(5):745-52
   PubMed Web of Science ®Google Scholar
• He X, He L, Hannon GJ. The guardian’s little helper: microRNAs in the p53 tumor suppressor network. Cancer Res 2007;67(23):11099-101
   PubMedGoogle Scholar
• Corney DC, Flesken-Nikitin A, Godwin AK, et al. MicroRNA-34b and MicroRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth. Cancer Res 2007;67(18):8433-8
   PubMed Web of Science ®Google Scholar
• Raver-Shapira N, Marciano E, Meiri E, et al. Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol Cell 2007;26(5):731-43
   PubMed Web of Science ®Google Scholar
• He L, He X, Lowe SW, Hannon GJ. microRNAs join the p53 network–another piece in the tumour-suppression puzzle. Nat Rev Cancer 2007;7(11):819-22
   PubMed Web of Science ®Google Scholar
• Christoffersen NR, Shalgi R, Frankel LB, et al. p53-independent upregulation of miR-34a during oncogene-induced senescence represses MYC. Cell Death Differ 2010;17(2):236-45
   PubMed Web of Science ®Google Scholar
• Xu Y, Liu L, Liu J, et al. A potentially functional polymorphism in the promoter region of miR-34b/c is associated with an increased risk for primary hepatocellular carcinoma. Int J Cancer 2011;128(2):412-17
   PubMed Web of Science ®Google Scholar
• Liu C, Kelnar K, Liu B, et al. The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med 2011;17(2):211-15
   PubMed Web of Science ®Google Scholar
• Merkel O, Asslaber D, Pinon JD, et al. Interdependent regulation of p53 and miR-34a in chronic lymphocytic leukemia. Cell Cycle 2010;9(14):2764-8
   PubMedGoogle Scholar
• Braun CJ, Zhang X, Savelyeva I, et al. p53-Responsive micrornas 192 and 215 are capable of inducing cell cycle arrest. Cancer Res 2008;68(24):10094-104
   PubMedGoogle Scholar
• Pichiorri F, Suh SS, Rocci A, et al. Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development. Cancer Cell 2010;18(4):367-81
   PubMed Web of Science ®Google Scholar
• Feng S, Cong S, Zhang X, et al. MicroRNA-192 targeting retinoblastoma 1 inhibits cell proliferation and induces cell apoptosis in lung cancer cells. Nucleic Acids Res 2011;39(15):6669-6678
   PubMedGoogle Scholar
• Sachdeva M, Zhu S, Wu F, et al. p53 represses c-Myc through induction of the tumor suppressor miR-145. Proc Natl Acad Sci USA 2009;106(9):3207-12
   PubMed Web of Science ®Google Scholar
• Spizzo R, Nicoloso MS, Lupini L, et al. miR-145 participates with TP53 in a death-promoting regulatory loop and targets estrogen receptor-alpha in human breast cancer cells. Cell Death Differ 2010;17(2):246-54
   PubMedGoogle Scholar
• Kerbel RS. Tumor angiogenesis. N Engl J Med 2008;358(19):2039-49
   PubMed Web of Science ®Google Scholar
• Teodoro JG, Parker AE, Zhu X, Green MR. p53-mediated inhibition of angiogenesis through up-regulation of a collagen prolyl hydroxylase. Science 2006;313(5789):968-71
   PubMed Web of Science ®Google Scholar
• Yu JL, Rak JW, Coomber BL, et al. Effect of p53 status on tumor response to antiangiogenic therapy. Science 2002;295(5559):1526-8
   PubMed Web of Science ®Google Scholar
• Bohlig L, Friedrich M, Engeland K. p53 activates the PANK1/miRNA-107 gene leading to downregulation of CDK6 and p130 cell cycle proteins. Nucleic Acids Res 2011;39(2):440-53
   PubMed Web of Science ®Google Scholar
• Thiery JP, Sleeman JP. Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol 2006;7(2):131-42
   PubMed Web of Science ®Google Scholar
• Hugo H, Ackland ML, Blick T, et al. Epithelial–mesenchymal and mesenchymal–epithelial transitions in carcinoma progression. J Cell Physiol 2007;213(2):374-83
   PubMed Web of Science ®Google Scholar
• Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 2009;9(4):265-73
   PubMed Web of Science ®Google Scholar
• Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002;2(6):442-54
   PubMed Web of Science ®Google Scholar
• Sleeman JP. The lymph node as a bridgehead in the metastatic dissemination of tumors. Recent Results Cancer Res 2000;157:55-81
   PubMedGoogle Scholar
• Chang CJ, Chao CH, Xia W, et al. p53 regulates epithelial-mesenchymal transition and stem cell properties through modulating miRNAs. Nat Cell Biol 2011;13(3):317-23
   PubMed Web of Science ®Google Scholar
• Gregory PA, Bert AG, Paterson EL, et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 2008;10(5):593-601
   PubMed Web of Science ®Google Scholar
• Wellner U, Schubert J, Burk UC, et al. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat Cell Biol 2009;11(12):1487-95
   PubMed Web of Science ®Google Scholar
• Korpal M, Lee ES, Hu G, Kang Y. The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem 2008;283(22):14910-14
   PubMed Web of Science ®Google Scholar
• Park SM, Gaur AB, Lengyel E, Peter ME. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev 2008;22(7):894-907
   PubMed Web of Science ®Google Scholar
• Shimono Y, Zabala M, Cho RW, et al. Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell 2009;138(3):592-603
   PubMed Web of Science ®Google Scholar
• Spaderna S, Schmalhofer O, Wahlbuhl M, et al. The transcriptional repressor ZEB1 promotes metastasis and loss of cell polarity in cancer. Cancer Res 2008;68(2):537-44
   PubMed Web of Science ®Google Scholar
• Comijn J, Berx G, Vermassen P, et al. The two-handed E box binding zinc finger protein SIP1 downregulates E-cadherin and induces invasion. Mol Cell 2001;7(6):1267-78
   PubMed Web of Science ®Google Scholar
• Yan HL, Xue G, Mei Q, et al. Repression of the miR-17-92 cluster by p53 has an important function in hypoxia-induced apoptosis. EMBO J 2009;28(18):2719-32
   PubMed Web of Science ®Google Scholar
• O’Donnell KA, Wentzel EA, Zeller KI, et al. c-Myc-regulated microRNAs modulate E2F1 expression. Nature 2005;435(7043):839-43
   PubMed Web of Science ®Google Scholar
• Kloosterman WP, Steiner FA, Berezikov E, et al. Cloning and expression of new microRNAs from zebrafish. Nucleic Acids Res 2006;34(9):2558-69
   PubMedGoogle Scholar
• van Rooij E, Quiat D, Johnson BA, et al. A family of microRNAs encoded by myosin genes governs myosin expression and muscle performance. Dev Cell 2009;17(5):662-73
   PubMed Web of Science ®Google Scholar
• Eischen CM, Lozano G. p53 and MDM2: antagonists or partners in crime? Cancer Cell 2009;15(3):161-2
   PubMedGoogle Scholar
• Dickens MP, Fitzgerald R, Fischer PM. Small-molecule inhibitors of MDM2 as new anticancer therapeutics. Semin Cancer Biol 2010;20(1):10-18
   PubMed Web of Science ®Google Scholar
• Saha MN, Micallef J, Qiu L, Chang H. Pharmacological activation of the p53 pathway in haematological malignancies. J Clin Pathol 2010;63(3):204-9
   Google Scholar
• Zhang J, Sun Q, Zhang Z, et al. Loss of microRNA-143/145 disturbs cellular growth and apoptosis of human epithelial cancers by impairing the MDM2-p53 feedback loop. Oncogene 2013;32(1):61-9
   PubMed Web of Science ®Google Scholar
• Xiao J, Lin H, Luo X, Wang Z. miR-605 joins p53 network to form a p53:miR-605:mdm2 positive feedback loop in response to stress. EMBO J 2011;30(3):524-32
   Google Scholar
• Ugalde AP, Ramsay AJ, de la Rosa J, et al. Aging and chronic DNA damage response activate a regulatory pathway involving miR-29 and p53. EMBO J 2011;30(11):2219-32
   PubMed Web of Science ®Google Scholar
• Park SY, Lee JH, Ha M, et al. miR-29 miRNAs activate p53 by targeting p85 alpha and CDC42. Nat Struct Mol Biol 2009;16(1):23-9
   PubMed Web of Science ®Google Scholar
• Hennessy BT, Smith DL, Ram PT, et al. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nature Rev Drug Discov 2005;4(12):988-1004
   PubMed Web of Science ®Google Scholar
• Mayo LD, Donner DB. The PTEN, Mdm2, p53 tumor suppressor-oncoprotein network. Trends Biochem Sci 2002;27(9):462-7
   PubMed Web of Science ®Google Scholar
• Suh SS, Yoo JY, Nuovo GJ, et al. MicroRNAs/TP53 feedback circuitry in glioblastoma multiforme. Proc Natl Acad Sci USA 2012;109(14):5316-21
   PubMed Web of Science ®Google Scholar
• Vaziri H, Dessain SK, Ng Eaton E, et al. hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 2001;107(2):149-59
   PubMed Web of Science ®Google Scholar
• Yamakuchi M, Ferlito M, Lowenstein CJ. miR-34a repression of SIRT1 regulates apoptosis. Proc Natl Acad Sci USA 2008;105(36):13421-6
   PubMed Web of Science ®Google Scholar
• Yamakuchi M, Lowenstein CJ. MiR-34, SIRT1 and p53: the feedback loop. Cell Cycle 2009;8(5):712-15
   PubMed Web of Science ®Google Scholar
• Hermeking H. p53 enters the microRNA world. Cancer Cell 2007;12(5):414-18
   PubMed Web of Science ®Google Scholar
• Yang X, Feng M, Jiang X, et al. miR-449a and miR-449b are direct transcriptional targets of E2F1 and negatively regulate pRb-E2F1 activity through a feedback loop by targeting CDK6 and CDC25A. Genes Dev 2009;23(20):2388-93
   PubMed Web of Science ®Google Scholar
• Lize M, Pilarski S, Dobbelstein M. E2F1-inducible microRNA 449a/b suppresses cell proliferation and promotes apoptosis. Cell Death Differ 2010;17(3):452-8
   Google Scholar
• Chang J, Nicolas E, Marks D, et al. miR-122, a mammalian liver-specific microRNA, is processed from hcr mRNA and may downregulate the high affinity cationic amino acid transporter CAT-1. RNA Biol 2004;1(2):106-13
   PubMedGoogle Scholar
• Fornari F, Gramantieri L, Giovannini C, et al. MiR-122/cyclin G1 interaction modulates p53 activity and affects doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res 2009;69(14):5761-7
   PubMed Web of Science ®Google Scholar
• Afanasyeva EA, Mestdagh P, Kumps C, et al. MicroRNA miR-885-5p targets CDK2 and MCM5, activates p53 and inhibits proliferation and survival. Cell Death Differ 2011;18(6):974-84
   PubMedGoogle Scholar
• Polager S, Ginsberg D. p53 and E2f: partners in life and death. Nat Rev Cancer 2009;9(10):738-48
   PubMed Web of Science ®Google Scholar
• Yang G, Zhang R, Chen X, et al. MiR-106a inhibits glioma cell growth by targeting E2F1 independent of p53 status. J Mol Med (Berlin) 2011;89(10):1037-50
   PubMed Web of Science ®Google Scholar
• Swarbrick A, Woods SL, Shaw A, et al. miR-380-5p represses p53 to control cellular survival and is associated with poor outcome in MYCN-amplified neuroblastoma. Nat Med 2010;16(10):1134-40
   PubMed Web of Science ®Google Scholar
• Shi XB, Xue L, Ma AH, et al. miR-125b promotes growth of prostate cancer xenograft tumor through targeting pro-apoptotic genes. Prostate 2011;71(5):538-49
   PubMed Web of Science ®Google Scholar
• Kumar M, Lu Z, Takwi AA, et al. Negative regulation of the tumor suppressor p53 gene by microRNAs. Oncogene 2011;30(7):843-53
   PubMed Web of Science ®Google Scholar
• Le MT, Teh C, Shyh-Chang N, et al. MicroRNA-125b is a novel negative regulator of p53. Genes Dev 2009;23(7):862-76
   PubMed Web of Science ®Google Scholar
• Zhang Y, Gao JS, Tang X, et al. MicroRNA 125a and its regulation of the p53 tumor suppressor gene. FEBS Lett 2009;583(22):3725-30
   PubMedGoogle Scholar
• Hu W, Chan CS, Wu R, et al. Negative regulation of tumor suppressor p53 by microRNA miR-504. Mol Cell 2010;38(5):689-99
   PubMed Web of Science ®Google Scholar
• Tweddle DA, Pearson AD, Haber M, et al. The p53 pathway and its inactivation in neuroblastoma. Cancer Lett 2003;197(1-2):93-8
   PubMed Web of Science ®Google Scholar
• Li J, Donath S, Li Y, et al. miR-30 regulates mitochondrial fission through targeting p53 and the dynamin-related protein-1 pathway. PLoS Genet 2010;6(1):e1000795
   PubMed Web of Science ®Google Scholar
• Tian S, Huang S, Wu S, et al. MicroRNA-1285 inhibits the expression of p53 by directly targeting its 3’ untranslated region. Biochem Biophys Res Commun 2010;396(2):435-9
   PubMedGoogle Scholar
• Wang Z, Liu M, Zhu H, et al. Suppression of p21 by c-Myc through members of miR-17 family at the post-transcriptional level. Int J Oncol 2010;37(5):1315-21
   PubMed Web of Science ®Google Scholar
• Wong P, Iwasaki M, Somervaille TC, et al. The miR-17-92 microRNA polycistron regulates MLL leukemia stem cell potential by modulating p21 expression. Cancer Res 2010;70(9):3833-42
   PubMed Web of Science ®Google Scholar
• Yoon AR, Gao R, Kaul Z, et al. MicroRNA-296 is enriched in cancer cells and downregulates p21WAF1 mRNA expression via interaction with its 3’ untranslated region. Nucleic Acids Res 2011;39(18):8078-91
   PubMed Web of Science ®Google Scholar
• Kan T, Sato F, Ito T, et al. The miR-106b-25 polycistron, activated by genomic amplification, functions as an oncogene by suppressing p21 and Bim. Gastroenterology 2009;136(5):1689-700
   PubMed Web of Science ®Google Scholar
• Zhang CZ, Zhang JX, Zhang AL, et al. MiR-221 and miR-222 target PUMA to induce cell survival in glioblastoma. Mol Cancer 2010;9:229
   PubMedGoogle Scholar
• Zhang C, Zhang J, Zhang A, et al. PUMA is a novel target of miR-221/222 in human epithelial cancers. Int J Oncol 2010;37(6):1621-6
   PubMed Web of Science ®Google Scholar
• Li JH, Xiao X, Zhang YN, et al. MicroRNA miR-886-5p inhibits apoptosis by down-regulating Bax expression in human cervical carcinoma cells. Gynecol Oncol 2011;120(1):145-51
   PubMed Web of Science ®Google Scholar
• Hu H, Du L, Nagabayashi G, et al. ATM is down-regulated by N-Myc-regulated microRNA-421. Proc Natl Acad Sci USA 2010;107(4):1506-11
   PubMed Web of Science ®Google Scholar
• Nakamura Y. ATM: the p53 booster. Nat Med 1998;4(11):1231-2
   PubMedGoogle Scholar
• Voorhoeve PM, le Sage C, Schrier M, et al. A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors. Cell 2006;124(6):1169-81
   PubMed Web of Science ®Google Scholar
• Cho WJ, Shin JM, Kim JS, et al. miR-372 regulates cell cycle and apoptosis of AGS human gastric cancer cell line through direct regulation of LATS2. Mol Cells 2009;28(6):521-7
   PubMedGoogle Scholar
• Rodriguez A, Griffiths-Jones S, Ashurst JL, Bradley A. Identification of mammalian microRNA host genes and transcription units. Genome Res 2004;14(10A):1902-10
   PubMed Web of Science ®Google Scholar
• Garzon R, Marcucci G, Croce CM. Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov 2010;9(10):775-89
   PubMed Web of Science ®Google Scholar
• Aagaard L, Rossi JJ. RNAi therapeutics: principles, prospects and challenges. Adv Drug Deliv Rev 2007;59(2-3):75-86
   PubMed Web of Science ®Google Scholar
• Zhao X, Pan F, Holt CM, et al. Controlled delivery of antisense oligonucleotides: a brief review of current strategies. Expert Opin Drug Deliv 2009;6(7):673-86
   PubMed Web of Science ®Google Scholar
• Mavrakis KJ, Wolfe AL, Oricchio E, et al. Genome-wide RNA-mediated interference screen identifies miR-19 targets in Notch-induced T-cell acute lymphoblastic leukaemia. Nat Cell Biol 2010;12(4):372-9
   PubMed Web of Science ®Google Scholar
• Olive V, Bennett MJ, Walker JC, et al. miR-19 is a key oncogenic component of mir-17-92. Genes Dev 2009;23(24):2839-49
   PubMed Web of Science ®Google Scholar
• Novotny GW, Sonne SB, Nielsen JE, et al. Translational repression of E2F1 mRNA in carcinoma in situ and normal testis correlates with expression of the miR-17-92 cluster. Cell Death Differ 2007;14(4):879-82
   PubMedGoogle Scholar
• Liu M, Wang Z, Yang S, et al. TNF-alpha is a novel target of miR-19a. Int J Oncol 2011;38(4):1013-22
   PubMed Web of Science ®Google Scholar
• Mendell JT. miRiad roles for the miR-17-92 cluster in development and disease. Cell 2008;133(2):217-22
   PubMed Web of Science ®Google Scholar
• Zhu S, Wu H, Wu F, et al. MicroRNA-21 targets tumor suppressor genes in invasion and metastasis. Cell Res 2008;18(3):350-9
   PubMed Web of Science ®Google Scholar
• Yamanaka Y, Tagawa H, Takahashi N, et al. Aberrant overexpression of microRNAs activate AKT signaling via down-regulation of tumor suppressors in natural killer-cell lymphoma/leukemia. Blood 2009;114(15):3265-75
   PubMed Web of Science ®Google Scholar
• Iliopoulos D, Jaeger SA, Hirsch HA, et al. STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer. Mol cell 2010;39(4):493-506
   PubMed Web of Science ®Google Scholar
• Hatley ME, Patrick DM, Garcia MR, et al. Modulation of K-Ras-dependent lung tumorigenesis by MicroRNA-21. Cancer Cell 2010;18(3):282-93
   PubMed Web of Science ®Google Scholar
• Pan X, Wang ZX, Wang R. MicroRNA-21: a novel therapeutic target in human cancer. Cancer Biol Ther 2011;10(12):1224-32
   Google Scholar
• Gabriely G, Yi M, Narayan RS, et al. Human glioma growth is controlled by microRNA-10b. Cancer Res 2011;71(10):3563-72
   PubMed Web of Science ®Google Scholar
• Liu Y, Zhao J, Zhang PY, et al. MicroRNA-10b targets E-cadherin and modulates breast cancer metastasis. Med Sci Monit 2012;18(8):BR299-308
   PubMed Web of Science ®Google Scholar
• Liu Z, Zhu J, Cao H, et al. miR-10b promotes cell invasion through RhoC-AKT signaling pathway by targeting HOXD10 in gastric cancer. Int J Oncol 2012;40(5):1553-60
   PubMedGoogle Scholar
• Lu YC, Chen YJ, Wang HM, et al. Oncogenic function and early detection potential of miRNA-10b in oral cancer as identified by microRNA profiling. Cancer Prev Res 2012;5(4):665-74
   PubMed Web of Science ®Google Scholar
• Willimott S, Wagner SD. miR-125b and miR-155 contribute to BCL2 repression and proliferation in response to CD40 ligand (CD154) in human leukemic B-cells. J Biol Chem 2012;287(4):2608-17
   PubMedGoogle Scholar
• Neilsen PM, Noll JE, Mattiske S, et al. Mutant p53 drives invasion in breast tumors through up-regulation of miR-155. Oncogene 2012;32(24):2992-3000
   PubMedGoogle Scholar
• McInnes N, Sadlon TJ, Brown CY, et al. FOXP3 and FOXP3-regulated microRNAs suppress SATB1 in breast cancer cells. Oncogene 2012;31(8):1045-54
   PubMed Web of Science ®Google Scholar
• Klein U, Lia M, Crespo M, et al. The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. Cancer Cell 2010;17(1):28-40
   PubMed Web of Science ®Google Scholar
• Bonci D, Coppola V, Musumeci M, et al. The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat Med 2008;14(11):1271-7
   PubMed Web of Science ®Google Scholar
• Guo LM, Pu Y, Han Z, et al. MicroRNA-9 inhibits ovarian cancer cell growth through regulation of NF-kappaB1. FEBS J 2009;276(19):5537-46
   PubMed Web of Science ®Google Scholar
• Wan HY, Guo LM, Liu T, et al. Regulation of the transcription factor NF-kappaB1 by microRNA-9 in human gastric adenocarcinoma. Mol Cancer 2010;9:16
   PubMed Web of Science ®Google Scholar